ViaNautis is exploiting its proprietary technology, polyNaut®, a nanovesicle platform using advanced polymer materials and machine learning, to direct nucleic a
Total raised: $25M
Investors 3
| Date | Name | Website |
| - | o2h ventur... | o2hventure... |
| 30.11.2023 | Cambridge ... | cambridgea... |
| 18.11.2023 | BGF Ventur... | bgf.co.uk |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 18.11.2023 | Series A | $25M | - |
Mentions in press and media 5
| Date | Title | Description | Source |
| 18.11.2023 | ViaNautis raises £20 million Series A financing to drive the... | ViaNautis Bio, a ground-breaking nanomedicine company at the forefront of genetic therapies, has com... | bgf.co.uk/... |
| 13.11.2023 | 4BIO Capital jointly leads $25 million Series A financing of... | - ViaNautis’s proprietary drug delivery platform polyNaut® is designed to deliver genetic therapeuti... | 4biocapita... |
| 13.11.2023 | ViaNautis Bio Raises $25M in Series A Financing | ViaNautis (formerly known as SomaServe), a Cambridge, UK-based nanomedicine company, raised $25M in ... | finsmes.co... |
| 13.11.2023 | 4BIO Capital jointly leads $25 million Series A financing of... | - | 4biocapita... |
| 13.11.2023 | 4BIO Capital jointly leads $25 million Series A financing of... | - ViaNautis’s proprietary drug delivery platform polyNaut® is designed to deliver genetic therapeuti... | 4biocapita... |